Syschem (India) FY26: Revenue Ran ₹574 Crore, Profit Multiplied 24x, and the Operating Margin Still Sits at 4%

General information and entertainment, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Consult a registered adviser before acting.

1 — At a Glance

Syschem (India) closed FY26 with sales of ₹574 crore, up from ₹332 crore a year earlier — a topline that has nearly doubled two years running. Net profit landed at ₹10.9 crore against ₹0.46 crore in FY25, a swing so large the profit-growth figure reads as 2,276%. That is the headline. The footnote is that operating margin finished the year at 4%, meaning the company earns roughly four paise of operating profit on every rupee of antibiotic it ships.

The tension sits right there. A penicillin-and-cephalosporin API maker in Haryana grew revenue faster than almost any peer in its table, yet converts that scale into a razor-thin operating line. Borrowings are effectively zero, cash on the books rose to ₹9.4 crore, and promoters lifted their stake to 60.86% by writing a cheque for warrants. Against that, the year also carried a ₹1.96 crore cyber fraud and a receivables pile that swelled to ₹144 crore.

A company can grow revenue 73% and still keep its margin in single digits — the question is which number the market chooses to watch. The year gives you both to look at.

2 — Introduction

Incorporated in 1993, Syschem (India) manufactures Active Pharmaceutical Ingredients and bulk drugs from a single manufacturing base at Village Bargodam, Tehsil Kalka, in Panchkula district, Haryana. The product roster is a lineup of antibiotics: Amoxycillin Trihydrate, Ampicillin Trihydrate, Cloxacillin Sodium, Dicloxacillin Sodium, Flucloxacillin Sodium (export only), Cephalexin and Cefadroxil — plus distillation of specialist solvents like Acetonitrile, Ethyl Acetate and THF.

The recent story is one of physical expansion. In January 2026 the company commenced commercial production at a new unit, Ganga (600 MTPA, for the cloxacillin family), alongside expansion of the existing Saru unit (1,200 MTPA, for Amoxicillin). Installed capacity now sits near 4,200 TPA, with a stated target of 8,000 TPA at an estimated cost of ₹14 crore and expected commissioning by December 2026.

The funding for growth came partly from the capital market. In March 2026, the board converted 55,00,000 warrants into equity at ₹49 per share, bringing in ₹20.21 crore and lifting paid-up capital to ₹49.01 crore. A further 86,72,500 warrants remain pending conversion. The board also reshuffled its top titles in June 2026, and the year was punctuated by a cyber-fraud disclosure — both covered further down.

3 — Business Model: WTF Do They Even Do?

Syschem makes the boring, essential middle of the medicine supply chain: the active ingredient inside the antibiotic, not the branded tablet on the pharmacy shelf. Amoxicillin, Ampicillin, Cephalexin, Cephadroxil — these are off-patent penicillins and cephalosporins that have been treating bacterial infections for decades. There is no molecule here waiting for FDA approval. The moat, such as it is, is chemistry, cost, and consistent supply.

The customer list reads like a directory of formulation companies — Angel Biogenics, Medico Remedies, Aura Pharmaceuticals, Coral Laboratories and others — firms that buy the bulk drug and turn it into finished dosages. The company serves roughly 100 customers, across about 14 Indian states and 10 international destinations, with export names spanning Nigeria, Kenya, Sri Lanka, Bangladesh and beyond. The revenue mix leans domestic: about 70% domestic in 9MFY26 against roughly 73% in FY25.

This is a volume game dressed as pharma. The presentation logs production climbing from 463 MT in Q1 to 1,239 MT in Q4 of the year. When your product is a commodity antibiotic sold by the tonne, the entire business reduces to a single sentence: can you make it cheaper than the next plant and still get paid on time? The 4% operating margin is the answer the market currently reads off the income statement — the company competes on price in a market where the buyer knows exactly what the molecule costs.

Does a business that grows tonnage 170% across a single fiscal year have a scale advantage arriving, or a margin that structurally refuses to move?

4 — Financials Overview

Figures are consolidated, in ₹ crore.

Q4 revenue of ₹219 crore was the largest quarter the company has printed. Operating profit rose to ₹9.37